Gritstone bio (NASDAQ:GRTS) was downgraded by both Jones Research and B. Riley on Wednesday, the day after the stock cratered in the wake of mixed data for Gritstone’s GRANITE cancer vaccine and ...

Gritstone bio (NASDAQ:GRTS) stock cratered 50% Tuesday, the day after the cancer vaccine developer reported data for its GRANITE immunotherapy and said it had retained a financial advisor to ...

Gritstone Bio GRTS is a clinical-stage biotechnology company focused on developing vaccines targeting multiple indications, including cancer. In the past week, the company’s stock lost 57.5%.

Gritstone Bio is laying off 40% of employees after delaying the start of a phase 2 trial testing its COVID-19 vaccine, which in turn pushed back the receipt of federal funds.. The layoffs ...

Gritstone bio is focused on developing vaccine-based immunotherapy candidates against cancer and infectious diseases. Find out why GRTS stock is a Hold.